Raymond James Financial
ATRA icon

Raymond James Financial’s Atara Biotherapeutics ATRA Stock Holding History

Raymond James Financial’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,021
Closed -$31K – 5090
2025
Q2 		$31K Buy
+4,021
New +$29.3K ﹤0.01% 5393

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial's ATRA Position: Q3 2025 in Review

Raymond James Financial sold out of Atara Biotherapeutics (ATRA) in Q3 2025, closing a stake of 4,021 shares — an estimated $31K sold.

Raymond James Financial first reported a position in ATRA in Q2 2025 and held it in 1 quarter. The position peaked at $31K in Q2 2025. 37 funds tracked by Wall St. Rank hold ATRA as of Q3 2025.

  • Raymond James Financial reported no remaining Atara Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 4,021 Atara Biotherapeutics shares in Q3 2025, an estimated $31K.
  • Raymond James Financial first reported a position in Atara Biotherapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Atara Biotherapeutics position peaked at $31K in Q2 2025.
  • 37 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.